Hypertension is the leading cause of cardiovascular disease and death. Despite increased knowledge of its importance in cardiovascular disease, the worldwide prevalence is still increasing and there is considerable scope for improvement of awareness, treatment and control. In this review, five major issues in hypertension management in secondary prevention of cardiovascular disease will be outlined. The first two issues will address hypertension diagnosis: out-of-office blood pressure measurements and the detection of secondary hypertension. The last three issues will address hypertension treatment: lifestyle modification, medication adherence and blood pressure targets. For each of the five issues, we will outline existing knowledge, gaps in existing knowledge, barriers preventing full implementation of guideline recommendations, and possible solutions to improve management of the current disquieting situation.
Introduction
Hypertension is strongly associated with cardiovascular disease and has become the leading risk factor for premature death worldwide. 1 About 58% of haemorrhagic stroke, 50% of ischaemic stroke, 55% of ischaemic heart disease and 58% of other cardiovascular diseases (including rheumatic and hypertensive heart disease, cardiomyopathy, rhythm or conduction disorders, aortic aneurysms, peripheral vascular disease and other cardiovascular diseases) have been attributed to high blood pressure (BP). 1 On top of that, its burden is still increasing. 2 In 2005 hypertension accounted for 9.2 million premature deaths and the loss of 189.6 million daily adjusted life-years (DALYs). Over the past decade this has increased to 10.7 million deaths and 211.8 million DALYs each year. 2 Despite these statistics, hypertension remains highly prevalent, underrecognised and under-controlled. In this review the extent of the problem will be illustrated by addressing hypertension prevalence, awareness and control. Five major topics in which scope for improvement in hypertension management of patients with cardiovascular disease exists will be outlined. First, we will discuss hypertension diagnosis by addressing out-of-office BP measurements and the detection of secondary hypertension. Subsequently, we will address hypertension treatment: lifestyle modification, medication adherence and BP targets. For each of the five issues, we will outline existing knowledge, gaps in existing knowledge, barriers preventing full implementation of guideline recommendations, and possible solutions to improve management of the current situation.
Hypertension prevalence, awareness and control 29% in those regions, this is outbalanced by the rising prevalence in low-and middle-income countries where an increase from 24% to 32% has been observed between 2000 and 2010. 3 In patients with established cardiovascular disease hypertension is even more common, occurring in 75% to 89% of the cases. 4, 5 Other concerns are the low awareness and the suboptimal treatment and control of hypertension. Globally, only 47% of the hypertensive population is aware of having high BP. 3 Even in high-income countries 37% is unaware of being hypertensive. Although in these regions treatment and control of hypertension have substantially increased from 2000 to 2010 (45% to 56%, and 18% to 28%, respectively), there is much improvement to be gained. 3 The rising global prevalence and burden of hypertension, together with the awareness of insufficient treatment and control, has led to collaboration and initiatives to reduce the negative consequences of this serious health problem. Authorities and healthcare organisations have developed and implemented strategies acting on different management levels, targeted at the individual patient as well as the entire population. 6 One of the most striking initiatives of the past decades is the 'Canadian Hypertension Education Program' (CHEP), which has been extremely successful in increasing hypertension awareness, control and treatment, and is therefore viewed as an international model for the development and implementation of healthcare recommendations. 7, 8 The success of CHEP is based on a multitude of factors: the distinct organisational structure compromising nearly all the country's hypertension experts and societies, agencies and pharmaceutical companies aimed at improving BP control; continuous updating of recommendations; consistent messaging; using a variety of dissemination tools; and training of local opinion leaders. 7, 8 CHEP was associated with the increased diagnosis of hypertension (57% to 84%), drug treatment (35% to 80%) and control of hypertension (13% to 68%), and large reductions in cardiovascular death and hospitalisation rates over the years 1992 to 2013. 9 Although the speed of improvement diminishes, this achievement is impressive compared to the improvements in other high-income countries. 3 
Out-of-office BP measurements
Automated office blood pressure (OBP) monitors, usually programmed to take two to three measurements, are extensively used to diagnose hypertension and evaluate treatment. However, these in-office measurements are associated with important limitations. Relying on OBP measurements can result in the misdiagnosis of hypertension, consequently leading to under-or overtreatment. 9 Moreover, relying on OBP measurements may lead to treatment delay and additional cardiovascular risk. 10, 11 As the protective effect already begins shortly after antihypertensive treatment initiation 10, 11 and a cumulative load of elevated systolic BP adds to cardiovascular risk, 12 this is particularly disadvantageous in patients with established cardiovascular disease who are at high risk of a new cardiovascular event. Therefore, out-of-office measurements (either home BP measurements or 24-hour ambulatory BP measurements) are essential to diagnose hypertension accurately, to prevent under-and overtreatment, and to initiate treatment as soon as the diagnosis of true hypertension has been made.
As increasing evidence shows an advantage of home BP measurements on BP control, use of out-of-office measurements has also been encouraged to monitor treatment. 13 A meta-analysis yielding 37 randomised controlled trials showed a À2.6 mmHg difference in 24-hour ambulatory BP in patients measuring their BP at home compared to patients in whom office measurements were performed.
14 This difference was even more pronounced when home BP measurements were combined with telemonitoring.
14 Possible explanations for the positive effect on BP control are the encouragement of patients to become more actively involved in their treatment, improvement of medication adherence and accelerated action to an increase in BP measured at home. 13 Although extensively recommended by the European, 15, 16 British, 17 American 18 and Canadian   19 guidelines on arterial hypertension, out-of-office measurements are not applied extensively enough. 20, 21 One of the explanations for the suboptimal use is the considerable portion of the practitioners being sceptical about the accuracy of out-of-office measurements, most importantly because they feel patients do not use these monitors in a systematically correct manner. 22 Furthermore, many practitioners are not familiar with out-of-office measurements. 22 Finally, the limited reimbursements provided by health insurance companies restrict the employment of out-of-office measurements. 22 The careful instruction of patients, training physicians (including general practitioners) on the use and interpretation of out-of-office monitors, and adequate allocation of financial resources, are possible solutions to overcome the current suboptimal use of these monitors.
Detection of secondary hypertension
In the past decade, detecting and treating secondary hypertension has become one of the main highlights in hypertension management; 5% to 10% of hypertensive patients have an increased BP due to a secondary van Kleef and Spieringcause. 23 Screening for these secondary causes is expensive and laborious. 23 However, it is important to detect secondary causes of hypertension at an early stage as specific treatment can lead to complete or partial normalisation of BP, which can more easily be achieved in younger patients. 24 Physicians should be aware of secondary hypertension in patients with juvenile hypertension, severe hypertension or resistant hypertension. 23 Resistant hypertensive patients are patients who remain hypertensive despite treatment with at least three antihypertensive drugs in adequate doses. Although the exact occurrence of secondary hypertension in this group is unknown, the prevalence is considered to be higher than in non-resistant hypertensive patients. 25, 26 It is important to eliminate treatable secondary causes of hypertension in these patients, before submitting them to new and invasive device-based treatments such as baroreflex activation therapy 27 or endovascular baroreflex amplification. 28 Although various guidelines focus on the detection and management of secondary hypertension by proposing screening tools, diagnostic tests and treatment strategies, 15, 23, 29 the condition is still underdiagnosed. 6 This is illustrated by recent observations in Germany and Italy where the level of knowledge and application of the guidelines on primary hyperaldosteronism was evaluated. 30 Primary hyperaldosteronism was markedly underdiagnosed due to unfamiliarity with the guidelines and their poor application. 30 In addition, there is a lack of algorithms providing physicians with the right tools to select those patients with a high probability of secondary hypertension and refer them to secondary or tertiary care. Future guidelines on the secondary causes of hypertension should therefore be brought to the broader public, and new diagnostic algorithms should be developed.
Lifestyle modification
It is widely known that lifestyle contributes to high BP. International guidelines therefore agree that lifestyle modification is the cornerstone of secondary prevention. 15, 19 However, patients with cardiovascular disease are underrepresented in previously performed interventional trials showing that reducing sodium intake, 31 moderating alcohol consumption, 32 adopting a diet rich in fruit, vegetables and low-fat dairy products, 33 regular exercise, 34 and weight reduction 35 leads to a decrease in BP.
As only a minority of the patients actually change their lifestyle after they have been diagnosed with hypertension, 36 and sustainability has proved difficult, a great challenge in this area exists. 37 The main explanations given in the literature are patients' unwillingness to change their lifestyle and inadequate counselling. 38 Intrinsic motivation to change lifestyle can be encouraged by adopting a more patient-centred approach, focussing only on those factors that are important to the individual patient. 38 Moreover, because many healthcare professionals believe they do not have the right skills in healthcare counselling, providing training programmes may assist them. 38 A more combined lifestyle approach using a multidisciplinary assessment of lifestyle was shown to be beneficial in patients with coronary heart disease and those at high risk of cardiovascular disease after 3 years follow-up. 39 In this study 30% more patients in the intervention group achieved BP targets compared to the control group. 39 This study opens up the potential for new intensive multidisciplinary strategies to improve lifestyle in patients at risk of hypertension that should be studied in more detail, particularly in patients with established cardiovascular disease.
Non-adherence to medication
Non-adherence to antihypertensive medication is one of the major contributors to poor BP control, increased cardiovascular risk and increased healthcare costs. Previous studies among hypertensive patients report poor adherence rates, varying from approximately 10% to 50%, depending on the population studied, the detection method used (subjective, indirect or direct measurement) and the definition of non-adherence. [40] [41] [42] A meta-analysis of six studies including more than 800 patients showed that the probability of good BP control was more than three times higher among adherent patients compared to non-adherent patients. 43 Apart from the high prevalence and its association with poor BP control, non-adherence has also been associated with an increased cardiovascular risk. In a meta-analysis which included studies assessing medication adherence in different ways, non-adherence resulted in a 23% higher risk of cardiovascular events. 44 A stronger effect has been observed, subsequently, in the CoSMO study, in which non-adherence (assessed using a pharmacy refill measure) was associated with a 87% higher risk of cardiovascular disease. 45 Due to this increased cardiovascular risk and its associated necessity of hospital admissions, doctor visits and reduced productivity, non-adherent patients account for significant healthcare and social costs. 46, 47 Non-adherence seems to be particularly important in patients with resistant hypertension. Antihypertensive medication adherence has been evaluated in renal denervation candidates unaware of being tested for medication adherence. Results from their blood samples showed that medication adherence was extremely low: 80% was either poorly adherent or non-adherent. 48 As patients with resistant hypertension are referred for invasive and costly, device-based therapies (renal denervation, baroreflex activation therapy or endovascular baroreflex amplification), it is utterly important to rule out treatable pseudoresistant hypertension before exposing patients to potentially harmful treatments.
Although there is convincing evidence showing that BP control can be improved by better treatment compliance, in clinical practice improving medication adherence is a great challenge. 49 Hence, in order to identify possible areas for improvement, comprehension of factors that contribute to non-adherence is of major importance. 47 These factors are summarised in Table 1 and can be divided into patient factors, physician factors and therapy factors. 47 Patient factors include lack of understanding, non-acceptance of the condition, lack of motivation or simply forgetting to take medications. 47, 49 Physician factors that contribute to non-adherence are: the inability to provide adequate and individualised information, giving inadequate instructions, lack of understanding of the patient's situation, lack of patient involvement in decision making, and failure to change therapy to achieve BP goals. 47 Therapy factors include the complexity of the dosing regimen and side effects of the medications. 50 Although presented separately, patient and physician factors are inextricably linked together.
Strategies to improve medication adherence by influencing patient and physician factors have been studied extensively. Informational interventions educating patients by i.e. group education, pharmacist education or periodic mailing of information seemed not to improve adherence. 51, 52 Interventions affecting patient behaviour, i.e. motivational counselling or patient reminders, generally increased medication adherence. 50, 52 Also, self-monitoring of BP has been shown to be beneficial. 53 The beneficial effect on medication adherence has additionally been observed in studies combining the different interventions, [50] [51] [52] particularly when delivered more frequently and over a longer period of time. 52 Therapeutic strategies to improve medication adherence are focussed on simplifying the medication regimen. In a meta-analysis adherence differed significantly between once-daily dosing and multiple daily dosing. 54 In addition, the prescription of combination pills has been shown to increase medication adherence in patients with hypertension 55 and cardiovascular disease. 56 Although it is likely that a broad approach, focussing on all the aforementioned factors, will improve medication adherence, interventions that provide behavioural support and/or simplify medication regimens seem most promising.
BP targets
It is widely known that lowering BP in patients with hypertension leads to a decrease in cardiovascular disease and death, particularly in high-risk patients. 57 However, less straightforward is the actual BP target we should aim for. Observational studies in individuals without prior cardiovascular disease have shown a progressive increase in cardiovascular risk at least when BP rises above 115/75 mmHg. 58 The large difference between this BP value and the current BP target of 140/90 mmHg is evident. Up until recently, evidence from randomised controlled trials to target BP below 140/90 mmHg was lacking. The ACCORD study group studied the effect of intensive BP lowering on major cardiovascular events in patients with type 2 diabetes mellitus. 59 They randomly assigned 4733 participants to intensive therapy, targeting systolic BP below 120 mmHg, or standard therapy, targeting systolic BP below 140 mmHg. 59 Although there was a trend towards improved outcomes, they were unable to show a significant reduction in major cardiovascular events (hazard ratio (HR) 0.88, 95% confidence interval (CI) 0.73-1.06) after a mean follow-up of 4.7 years. 59 After the ACCORD trial, the SPRINT study group examined the same question among patients without diabetes mellitus. 60 SPRINT randomly assigned 9361 patients with an increased cardiovascular risk (including patients with clinical cardiovascular disease) to intensive or standard treatment, applying similar BP targets as in ACCORD. After a median followup time of 3.3 years the study was ended prematurely when a significantly lower rate of cardiovascular events Lack of patient involvement in decision making Failure to change therapy to achieve BP goals was observed in the intensive treatment group (HR 0.75, 95% CI 0.64-0.89). Both ACCORD and SPRINT showed an increased rate of serious adverse events of hypotension, electrolyte abnormalities and acute kidney injury or kidney failure in the intensive treatment group.
Although the evidence supports the strategy to aim for lower BP targets, a great discussion on whether and how to implement this BP target into new hypertension guidelines is going on. One of the major questions is how to translate the BP target used in SPRINT (where BP was assessed by unattended automated OBP measurements) into general BP targets, because attended OBP measurements are estimated to be 10-15 mmHg higher than the unattended OBP measurements used in SPRINT. 61, 62 Finally, implementation of lower BP targets involves socioeconomic issues: increased demand for antihypertensive medications; more frequent clinical visits due to intensified treatment and adverse events; and the costs associated with both.
Conclusion
Although we are on the right track, further steps should be taken to reduce cardiovascular risk associated with hypertension. Significant developments in diagnosing, monitoring and treating hypertension have been made, and have been captured in the guidelines. However, guidelines should be implemented more extensively to improve diagnosis and treatment according to standards, with particular emphasis on: (a) extending the use of out-of-office BP measurements (instruct patients, train physicians and increase financial resources); (b) improving the detection of secondary hypertension (develop better diagnostic algorithms, bring current guidelines to the attention of the broader public); (c) changing lifestyle (intensive multidisciplinary strategies may be promising); (d) increasing medication adherence (apply behavioural interventions and simplify treatment regimens); and (e) targeting therapy to lower BP levels (define the optimal BP target) ( Table 2) .
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